malformations related to sibutramine use in early pregnancy. Our aim is to report outcomes of 10 additional cases.

Methods: We report a series of observations from two counseling centers for pregnant women and their doctors: a center for drug safety in pregnancy and lactation (“Babyrisk”) in St Petersburg (West of Russia) and counseling center of clinical pharmacology in a neonatal pediatri
cal hospital in Vladivostok (East of Russia).

Results: Ten women approached the above-mentioned centers during 2011 and 2012. All were taking sibutra
mine for weight loss without official prescription and dis
covered unplanned pregnancy while on sibutramine. All of
them stopped sibutramine in the first trimester: four
women on gestational week 2; five on week 4 to 5; one
woman on week 6 to 7. Median age of the women was 29
(ranging 23–35) years, sibutramine daily dose was 15 mg
in 6 and 10 mg in four cases. All cases were followed-up
telephone interview and checked with city registries of
inborn anomalies. Nine women gave birth to normal
healthy babies. No cardiovascular complications were
reported. In one case, pregnancy was terminated on week 12
due to fetal malformations: cystic lymphangioma and
malformation of upper limbs. Genetic evaluation resulted
in detection of chromosome 13 and 18 trisomy.

Conclusion: Our report adds to a total number of
cases demonstrating general safety of sibutramine use in
early pregnancy, although exposures of sibutramine and
its metabolites presumably exceeded “all-or-none” period
in only half of the cases.

22. Beta-2 Agonists and Montelukast in Pregnant Asthmatic Patients

M. Kadioglu,1 I. Erkoseoglu,1 T. Aran,1 D. Altintas-Aykan,1 E. Yaris,1 N.I. Kalyoncu,1 and E. Yenilmez2

1Karadeniz Technical University Faculty of Medicine Teratogen Information Service, Trabzon, Turkey.

Background: Asthma is one of the most common medical conditions encountered during pregnancy, occurring in 3% to 8% of pregnant women. Uncontrolled asthma is associ
ated with increased risk of preeclampsia, preterm birth, perinatal death, or maternal and fetal complications such as low birth weight. National Asthma Education and Pre
vention Program (NAEPP) recommends using short-acting beta2 agonist albuterol (salbutamol) during pregnancy. Although no increased risk for congenital anomalies is
reported in the studies related to salmeterol and formoterol, congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal salbutamol use.
Montelukast is classified as U.S. Food and Drug Administra
tion Category B. However, the manufacturer states that
congenital limb defects have been rarely reported in the
offspring(s) of women exposed to montelukast during pregnancy without established causality. Due to the lack of human safety information, montelukast should be used in
pregnancies only if the potential benefit outweighs the
potential risk to the fetus. In this study, the pregnancy out
comes of the women exposed to beta-2 agonists and/or
montelukast are evaluated.

Methods: The pregnant women who have applied to
“Karadeniz Technical University Teratogen Information Service” between 1999 and 2013, were included in this
case series of maternal beta-2 agonists and/or monteluk
ast exposure. During the postpartum period, development of
babies was followed up for a year.

Results: The results of 37 pregnant women exposed to
beta2 agonists and/or montelukast are evaluated. Seven of
37 women used both beta-2 agonists and montelukast. Six
teen of them used only beta-2 agonists, and 14 of them
used montelukast. In 33 pregnancies, multiple drug expo
sure was also observed. Five of the pregnancies were ended
with spontaneous abortions; four with elective termina
tions. One of the pregnancies was exposed to both salbuta
mol and ergotamine, ended with preterm delivery and
death. Congenital hypothyroidism is observed in the child
of woman exposed to salbutamol in preconceptional period.
The rest of deliveries were on term, except one preterm
and premature baby, and all of them are healthy still.

Conclusion: In this case series, the presence of monte
lukast exposure both in the observed congenital hypothy
roidism case and in three of five spontaneous abortion
cases is remarkable.

23. Pregnancy Outcome following Maternal Exposure to
Pregabalin: Preliminary Results of a Collaborative ENTIS and
Motherisk Study

U. Winterfeld,1 P. Merlob,2 D. Baud,3 A. Panchaud,1 L.E. Roth
uien,1 N. Bernard,4 T. Vial,4 M. Yates,5 A. Pistelli,6 M. Ellfolk,7
G. Eleftheriou,6 L.C. de Bries,8 P. Bozzo,9 A.-P. Jonville-Bera,11
M. Kadioglu,12 J. Biollaz,1 and T. Buclin1

1STIS and Division of Clinical Pharmacology, University Hospital,
Lausanne, Switzerland, 2BELTIS Rubin Medical Center and Sack
ler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel,
3Materno-Fetal and Obstetrics Research Unit, University Hospi
tal, Lausanne, Switzerland, 4Centre Régional de Pharmacovigi
lance, Hospices Civils de Lyon, Lyon, France, 5UKTIS, Regional
Drug and Therapeutics Centre, Newcastle upon Tyne, United
Kingdom, 6Centro di Riferimento Regionale di Tossicologia Peri
natale, Azienda Ospedaliero Universitaria Carughi, Florence, Italy.
7Teratology Information Service, Helsinki University Cen
tral Hospital and HUSLAB, Helsinki, Finland, 8Poison Control,
Bergamo, Italy, 9TIS, Netherlands Pharmacovigilance Centre
Lareh, Den Bosch, the Netherlands, 10The Motherisk Program,
The Hospital for Sick Children, Toronto, Canada, 11Centre de
Pharmacovigilance de Tours, CHRU, Tours, France, 12Karadeniz
Background: Animal studies have shown reproductive toxicity of pregabalin at doses higher than those used in humans. Currently no published data are available on pregnancy outcomes in patients exposed to pregabalin. In this study we investigate the risk for major birth defects and other pregnancy outcomes with exposure to pregabalin during pregnancy.

Methods: This is a multicenter (n = 9), observational prospective cohort study comparing pregnancy outcomes after exposure to pregabalin with a matched control group (no exposure to medications known to be teratogenic or to any antiepileptic drug). Data were collected by members of the European Network of Teratology Information Services (ENTIS) and Motherisk during individual risk counseling between 2004 and 2013.

Results: We collected data from 173 exposed pregnancies and 692 controls. Altogether, major birth defects were reported more frequently in pregnancies exposed to pregabalin than in the control group (8.5% versus 2.8%; unadjusted odds ratio [OR], 3.2; 95% confidence interval [CI], 1.3–7.5, p = 0.002). After exclusion of chromosomal syndromes, a non-significant trend towards a higher rate of birth defects in the pregabalin group persisted (5.4% versus 2.0%; OR, 2.8; 95% CI, 0.9–7.9, p = 0.06). Further analysis will focus on clarification of some anomalies and possible confounding factors. The rate of live births was noticeably lower in the pregabalin group (71.1% vs. 85.4%; p < 0.001), primarily due to a higher rate of both elective (10.4% vs. 4.8%; p = 0.01) and medical (5.2% vs. 1.7%; p = 0.02) pregnancy terminations. In addition, the crude rate of spontaneous abortion (14.4% vs. 8.0%, p = 0.03) was higher in the pregabalin group. Preterm birth rates (<37 weeks) (8.9% vs. 8.0%; p = 0.72), gestational age at birth (median 40 weeks; interquartile range [IQR], 38–40 vs. median 40; IQR, 38–41; p = 0.58), and birth weight (median, 3290 g; IQR, 3000–3640 vs. 3350 g; IQR, 3020–3644; p = 0.55) did not differ between the groups.

Conclusion: These preliminary results raise a possible signal for an increased crude rate of birth defects and spontaneous abortions after exposure to pregabalin during pregnancy. Further analyses are still needed to exclude biases or confounders. These results call for further confirmation through independent studies.

24. Pregnancy Outcome after Dimethyl Fumarate Treatment during Early Pregnancy: A Prospective Case Series
C. Weber-Schoendorfer,1 E. Wacker,1 and C. Schaefer2

Background: Dimethyl fumarate containing drugs have been used for treating psoriasis in Germany for many years. However, there are no published data on its use during pregnancy. Only recently dimethyl fumarate has been licensed for multiple sclerosis (MS). From clinical MS studies, pregnancy outcomes of 25 dimethyl fumarate recipients are available resulting in 15 healthy live births, 3 spontaneous abortions, and 7 elective terminations (1). The aim of this case series was to evaluate the risk of birth defects, spontaneous abortion, and elective termination of pregnancy after first trimester exposure to dimethyl fumarate.

Methods: Pregnancy outcomes of women on dimethyl fumarate were evaluated in a prospective observational case series. The sample consists of pregnancies identified by our institute which was spontaneously contacted by health care professionals and pregnant women for drug risk assessment during pregnancy.

Results: Follow-up of pregnancy outcome after dimethyl fumarate exposure was initiated in 43 cases and completed in 34. Five cases were lost to follow-up and four pregnancies are still ongoing. Thirty-two women with completed follow-up were treated for psoriasis and 2 for other skin disorders. Median maternal age was 31 years, and body mass index was 23.9. The majority (90.6%) did not drink any alcohol during pregnancy, and 62.5% were non-smokers. Less than the half (47%) had at least one previous parity. Dosage of dimethyl fumarate varied between 120 mg/d and 720 mg/d. Except for one pregnancy with pre-conception use only, treatment was started prior to conception (n = 30) or shortly after conception (n = 3) and was usually stopped after recognition of pregnancy, at a median gestational age of 6 weeks after the last menstrual period. There were two birth defects among 27 live-born infants, of which one was relatively major (horseshoe kidney). Thirteen girls and 14 boys with a median birth weight of 3410 g were delivered at a median gestational age of 39 weeks. Four early and one late spontaneous abortions occurred. Two pregnancies were electively terminated for social reasons.

Conclusion: Our limited data do not provide evidence for an increased risk of adverse pregnancy outcome after dimethyl fumarate containing drugs in early pregnancy.

25. Pramipexole Use in Pregnancy: Three Cases in the Netherlands
Benedikte-Noë1 Cappers-Maarschalkerweerd,1 and Eugène Puijenbroek1

1Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, the Netherlands, 2University of Groningen, Department of Pharmacy, Pharmacotherapy and Pharmaceutical Care, Groningen, the Netherlands.

Background: Pramipexole is used for the treatment of restless legs and Parkinson’s disease. When treatment in...